92 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Jagiellonian University Medical College
Rational design of dual peptides targeting ghrelin and Y2 receptors to regulate food intake and body weight.
Universit£T Leipzig
Design and Synthesis of Peptide YY Analogues with C-terminal Backbone Amide-to-Ester Modifications.
University of Copenhagen
Dimeric argininamide-type neuropeptide Y receptor antagonists: chiral discrimination between Y1 and Y4 receptors.
University of Regensburg
Replacement of Thr32 and Gln34 in the C-terminal neuropeptide Y fragment 25-36 by cis-cyclobutane and cis-cyclopentane β-amino acids shifts selectivity toward the Y(4) receptor.
University of Regensburg
The discovery of potent selective NPY Y(2) antagonists.
Janssen Research and Development
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
Institute of Organic Synthesis
Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
University of Siena
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
Broad Institute of Mit and Harvard
The identification of a series of novel, soluble non-peptidic neuropeptide Y Y2 receptor antagonists.
Glaxosmithkline
Synthesis and SAR of selective small molecule neuropeptide Y Y2 receptor antagonists.
The Scripps Research Institute
Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.
Aska Pharmaceutical
Discovery of novel orally active ureido NPY Y5 receptor antagonists.
Schering-Plough Research Institute
Truncated, branched, and/or cyclic analogues of neuropeptide Y: importance of the pancreatic peptide fold in the design of specific Y2 receptor ligands.
Salk Institute
Discovery of Lu AA33810: a highly selective and potent NPY5 antagonist with in vivo efficacy in a model of mood disorder.
Lundbeck Research Usa
The discovery and synthesis of JNJ 31020028, a small molecule antagonist of the Neuropeptide Y Y2 receptor.
Johnson & Johnson Pharmaceutical Research & Development
Discovery of pyridone-containing imidazolines as potent and selective inhibitors of neuropeptide Y Y5 receptor.
Tsukuba Research Institute
Red-fluorescent argininamide-type NPY Y1 receptor antagonists as pharmacological tools.
Universit£T Regensburg
Discovery and evaluation of pyrazolo[1,5-a]pyrimidines as neuropeptide Y1 receptor antagonists.
Pfizer
Spiroindolones, a potent compound class for the treatment of malaria.
Swiss Tropical and Public Health Institute
Synthesis and structure-activity relationship of N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-5-(2-pyridinyl)-1,3-thiazol-2-amines derivatives as NPY Y5 antagonists.
Glaxosmithkline
A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.
Università
Discovery and SAR of cyclic isothioureas as novel NPY Y1 receptor antagonists.
Schering-Plough Research Institute
[Lys(DOTA)4]BVD15, a novel and potent neuropeptide Y analog designed for Y1 receptor-targeted breast tumor imaging.
University of Sherbrooke
Identification of positron emission tomography ligands for NPY Y5 receptors in the brain.
Tsukuba Research Institute
Synthesis and evaluation of a series of 2,4-diaminopyridine derivatives as potential positron emission tomography tracers for neuropeptide Y Y1 receptors.
Tsukuba Research Institute
Design, synthesis and evaluation of a novel cyclohexanamine class of neuropeptide Y Y1 receptor antagonists.
Tsukuba Research Institute
The identification and optimisation of novel and selective diamide neuropeptide Y Y2 receptor antagonists.
Glaxosmithkline
8-amino-6-(arylsulphonyl)-5-nitroquinolines: novel nonpeptide neuropeptide Y1 receptor antagonists
TBA
Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.
Tsukuba Research Institute
Discovery of tetrasubstituted imidazolines as potent and selective neuropeptide Y Y5 receptor antagonists: reduced human ether-a-go-go related gene potassium channel binding affinity and potent antiobesity effect.
Tsukuba Research Institute
Guanidine-acylguanidine bioisosteric approach in the design of radioligands: synthesis of a tritium-labeled N(G)-propionylargininamide ([3H]-UR-MK114) as a highly potent and selective neuropeptide Y Y1 receptor antagonist.
University of Regensburg
Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists.
Banyu Tsukuba Research Institute
Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivatives.
Banyu Tsukuba Research Institute
(9S)-9-(2-hydroxy-4,4-dimethyl-6-oxo-1-cyclohexen-1-yl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-xanthen-1-one, a selective and orally active neuropeptide Y Y5 receptor antagonist.
Tsukuba Research Institute
Novel selective neuropeptide Y2 receptor PEGylated peptide agonists reduce food intake and body weight in mice.
Bayer Pharmaceuticals
Stereochemistry-Driven Interactions of α,γ-Peptide Ligands with the Neuropeptide Y Y
University of Regensburg
Structure-Activity Relationship Study of the High-Affinity Neuropeptide Y
Leipzig University
A long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake in mice.
Bayer Pharmaceuticals
Double Methotrexate-Modified Neuropeptide Y Analogues Express Increased Toxicity and Overcome Drug Resistance in Breast Cancer Cells.
Universitat Leipzig
Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar affinity.
University of Cincinnati
N-Terminus to Arginine Side-Chain Cyclization of Linear Peptidic Neuropeptide Y Y
University of Regensburg
Discovery and SAR of potent, orally available and brain-penetrable 5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen- and 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulen derivatives as neuropeptide Y Y5 receptor antagonists.
Novartis Pharma
Novel non-peptidic neuropeptide Y Y2 receptor antagonists.
Johnson & Johnson Pharmaceutical Research and Development
Differentially functionalized diamines as novel ligands for the NPY2 receptor.
Bristol-Myers Squibb Pharmaceutical Research Institute
Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis.
Syracuse University
Engineering of a Potent, Long-Acting NPY2R Agonist for Combination with a GLP-1R Agonist as a Multi-Hormonal Treatment for Obesity.
The Scripps Research Institute
Synthesis and structure-activity relationships of trisubstituted phenyl urea derivatives as neuropeptide Y5 receptor antagonists.
Amgen
Highly selective and potent neuropeptide Y (NPY) Y1 receptor antagonists based on [Pro(30), Tyr(32), Leu(34)]NPY(28-36)-NH2 (BW1911U90).
University of Cincinnati and Va Medical Centers
High Affinity Agonists of the Neuropeptide Y (NPY) Y4 Receptor Derived from the C-Terminal Pentapeptide of Human Pancreatic Polypeptide (hPP): Synthesis, Stereochemical Discrimination, and Radiolabeling.
University of Regensburg
Structure-activity studies including a Psi(CH(2)-NH) scan of peptide YY (PYY) active site, PYY(22-36), for interaction with rat intestinal PYY receptors: development of analogues with potent in vivo activity in the intestine.
University of Cincinnati Medical Center
Structure-activity relationships of neuropeptide Y Y1 receptor antagonists related to BIBP 3226.
University of Regensburg
Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists.
Novartis Pharma
Pharmacological treatment of obesity: therapeutic strategies.
The R. W. Johnson Pharmaceutical Research Institute
Bis(31/31') ([CYS(31), Trp(32), Nva(34)] NPY-(31-36)): a specific NPY Y-1 receptor antagonist.
University of Cincinnati Medical Center
N(ω)-Carbamoylation of the Argininamide Moiety: An Avenue to Insurmountable NPY Y1 Receptor Antagonists and a Radiolabeled Selective High-Affinity Molecular Tool ([(3)H]UR-MK299) with Extended Residence Time.
Cnrs/Ipbs (Institut De Pharmacologie Et Biologie Structurale)
Defining structural requirements for neuropeptide Y receptors using truncated and conformationally restricted analogues.
Salk Institute
Neuropeptide Y: Y1 and Y2 affinities of the complete series of analogues with single D-residue substitutions.
Salk Institute
Novel modified carboxy terminal fragments of neuropeptide Y with high affinity for Y2-type receptors and potent functional antagonism at a Y1-type receptor.
Burroughs Wellcome
Antiobesity and emetic effects of a short-length peptide YY analog and its PEGylated and alkylated derivatives.
Takeda Pharmaceutical
Highly potent antiobesity effect of a short-length peptide YY analog in mice.
Takeda Pharmaceutical
Identification and biological evaluation of thiazole-based inverse agonists of RORγt.
Phenex Pharmaceuticals
Potent antiobesity effect of a short-length peptide YY-analogue continuously administered in mice.
Takeda Pharmaceutical
Antiobesity Effect of a Short-Length Peptide YY Analogue after Continuous Administration in Mice.
Takeda Pharmaceutical
2-(6-Phenyl-1H-indazol-3-yl)-1H-benzo[d]imidazoles: design and synthesis of a potent and isoform selective PKC-zeta inhibitor.
Pfizer
Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors.
Duquesne University
Design, synthesis, and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase.
Burnham Institute For Medical Research
Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity.
University of St. Andrews
Carbonic anhydrase inhibitors: the membrane-associated isoform XV is highly inhibited by inorganic anions.
Universita Degli Studi Di Firenze
Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.
Pfizer
The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases.
The Scripps Research Institute
Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties.
Amgen